CO5271716A1 - Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida - Google Patents
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituidaInfo
- Publication number
- CO5271716A1 CO5271716A1 CO00085285A CO00085285A CO5271716A1 CO 5271716 A1 CO5271716 A1 CO 5271716A1 CO 00085285 A CO00085285 A CO 00085285A CO 00085285 A CO00085285 A CO 00085285A CO 5271716 A1 CO5271716 A1 CO 5271716A1
- Authority
- CO
- Colombia
- Prior art keywords
- crystals
- carboxamine
- tetrahydroquinoline
- replaced
- imf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5271716A1 true CO5271716A1 (es) | 2003-04-30 |
Family
ID=22609901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00085285A CO5271716A1 (es) | 1999-11-30 | 2000-11-09 | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1246804A1 (fr) |
| JP (1) | JP2003515592A (fr) |
| KR (1) | KR20020058057A (fr) |
| CN (1) | CN1402711A (fr) |
| AP (1) | AP2002002531A0 (fr) |
| AU (1) | AU1048801A (fr) |
| BG (1) | BG106854A (fr) |
| BR (1) | BR0015836A (fr) |
| CA (1) | CA2392979A1 (fr) |
| CO (1) | CO5271716A1 (fr) |
| EA (1) | EA200200510A1 (fr) |
| EC (1) | ECSP003792A (fr) |
| EE (1) | EE200200277A (fr) |
| GT (1) | GT200000199A (fr) |
| HU (1) | HUP0203521A2 (fr) |
| IL (1) | IL149097A0 (fr) |
| IS (1) | IS6338A (fr) |
| MA (1) | MA26845A1 (fr) |
| MX (1) | MXPA02005354A (fr) |
| NO (1) | NO20022558L (fr) |
| OA (1) | OA12099A (fr) |
| PA (1) | PA8506301A1 (fr) |
| PE (1) | PE20010904A1 (fr) |
| PL (1) | PL355892A1 (fr) |
| TN (1) | TNSN00231A1 (fr) |
| TR (1) | TR200201446T2 (fr) |
| UY (1) | UY26454A1 (fr) |
| WO (1) | WO2001040190A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| TNSN03139A1 (fr) | 2001-06-21 | 2005-12-23 | Pfizer Prod Inc | Formulations auto-emulsionnables d'inhibiteurs de la proteine de transfert d'ester de cholesteryle |
| GT200200170A (es) | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
| PT1469833T (pt) * | 2002-02-01 | 2021-07-13 | Bend Res Inc | Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado |
| EP1920766B1 (fr) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Compositions pharmaceutiques de dispersions amorphes de médicaments et matériaux formant des microphases lipophiles |
| ATE395044T1 (de) | 2002-02-01 | 2008-05-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien |
| ES2277142T3 (es) | 2002-08-30 | 2007-07-01 | Japan Tobacco Inc. | Compuesto de dibencilamina y su uso medicinal. |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US7211672B2 (en) | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| BR0317521A (pt) | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa |
| JP2006521344A (ja) * | 2003-03-28 | 2006-09-21 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体 |
| JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
| DK1670768T3 (da) | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
| JP4922924B2 (ja) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害薬 |
| EP1761521A1 (fr) * | 2004-06-24 | 2007-03-14 | Eli Lilly And Company | Composés et procédés destinés à traiter la dyslipidémie |
| WO2006033001A1 (fr) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Composes de quinoline |
| WO2006033004A1 (fr) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Composes de quinoline en tant qu'inhibiteurs de cetp |
| WO2006091674A1 (fr) | 2005-02-24 | 2006-08-31 | Millennium Pharmaceuticals, Inc. | Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires |
| WO2006098394A1 (fr) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AR065670A1 (es) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| WO2010075068A1 (fr) | 2008-12-16 | 2010-07-01 | Schering Corporation | Dérivés de pyridopyrimidine et leurs procédés d'utilisation |
| TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸 |
| MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| WO1998033775A1 (fr) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | Derives de l'-1-acyl-1,2-dihydroquinoline substituee en 2 augmentant la concentration en cholesterol hdl |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/fr not_active Application Discontinuation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EP EP00971662A patent/EP1246804A1/fr not_active Withdrawn
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 CA CA002392979A patent/CA2392979A1/fr not_active Abandoned
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1246804A1 (fr) | 2002-10-09 |
| EA200200510A1 (ru) | 2002-10-31 |
| AP2002002531A0 (en) | 2002-06-30 |
| JP2003515592A (ja) | 2003-05-07 |
| IL149097A0 (en) | 2002-11-10 |
| CN1402711A (zh) | 2003-03-12 |
| AU1048801A (en) | 2001-06-12 |
| KR20020058057A (ko) | 2002-07-12 |
| CA2392979A1 (fr) | 2001-06-07 |
| WO2001040190A1 (fr) | 2001-06-07 |
| PL355892A1 (en) | 2004-05-31 |
| TR200201446T2 (tr) | 2002-11-21 |
| MXPA02005354A (es) | 2002-12-11 |
| UY26454A1 (es) | 2001-07-31 |
| PA8506301A1 (es) | 2002-08-26 |
| GT200000199A (es) | 2002-05-23 |
| EE200200277A (et) | 2003-10-15 |
| TNSN00231A1 (fr) | 2002-05-30 |
| HUP0203521A2 (hu) | 2003-02-28 |
| OA12099A (en) | 2006-05-04 |
| BG106854A (bg) | 2002-12-29 |
| ECSP003792A (es) | 2002-04-23 |
| NO20022558D0 (no) | 2002-05-29 |
| IS6338A (is) | 2002-04-12 |
| NO20022558L (no) | 2002-05-29 |
| BR0015836A (pt) | 2002-08-06 |
| MA26845A1 (fr) | 2004-12-20 |
| PE20010904A1 (es) | 2001-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5271716A1 (es) | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida | |
| ATE181551T1 (de) | Taxol-derivate | |
| DK0914119T3 (da) | Fremgangsmåde til fremstilling af faste orale dosisformer af valsartan | |
| EP0931788A3 (fr) | Inhibiteurs de la métalloprotéinase | |
| DK0788496T3 (da) | Inhibitorer for syntese af apolipoprotein-B | |
| DK0937055T3 (da) | Fremgangsmåde til fremstilling af d,I-alfa-tocopherol | |
| ATE236123T1 (de) | Thermodynamisch stabile modifizierung von 1-(4- carbazolyloxy)-3- (2-(2- methoxyphenoxy)ethylamino)-2-propanol, verfahren zu ihrer herstellung und ihre enthaltende pharmazeutische zusammensetzungen | |
| DE69009746D1 (de) | Derivate von n-phenylbenzamid mit antiulcerativer sowie antiallergischer aktivität und verfahren zu ihrer herstellung. | |
| ATE171188T1 (de) | In 15-stellung substituierte 4-azasteroide | |
| SE8904298D0 (sv) | New compounds | |
| DK293088A (da) | Inhibitorer af dopamin-beta-hydroxylase | |
| CO5150178A1 (es) | Bromohidrato de eletriptan monohidrato y procedimiento para su preparacion | |
| SE9902550D0 (sv) | New crystalline forms | |
| DE60031663D1 (de) | Flammschutzmittel, verfahren zu dessen herstellung und flammschutzmittelharzzusammensetzung dieses enthaltend | |
| GB2324091B (en) | Metalloproteinase inhibitors | |
| IT1293777B1 (it) | Processo per la preparazione di tetraazamacrocicli | |
| TR199701298T1 (xx) | Tetralinler. | |
| AR002978A1 (es) | Compuestos benzamidas, composiciones farmacéuticasque los contienen, metodos para preparar los mismos y el uso de los mismos. | |
| CO5280205A1 (es) | Forma cristalina de eplerenona . | |
| AP2002002651A0 (en) | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) | |
| ES2085386T3 (es) | Procedimiento para la preparacion de tacs cristalino. | |
| SE9402241D0 (sv) | Inhibitor | |
| CO5080790A1 (es) | Derivados de acridina y procedimiento para la preparacion de dichos derivados | |
| CO5271714A1 (es) | Cristales de inhibidor del intercambiador de sodio-hidrogeno | |
| NO901422D0 (no) | Fremgangsmaate for fremstilling av alfa-glucosidase-inhibitorer. |